• Mashup Score: 0
    MDS in younger patients: the importance of curative approaches & optimizing timing of alloSCT - 8 hour(s) ago

    Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the optimal treatment strategy for younger patients with myelodysplastic syndromes (MDS), highlighting the need for curative approaches and the importance of optimizing timing for allogeneic stem cell transplantation (alloSCT). He emphasizes the potential of new technologies, including artificial intelligence, to make informed decisions for individual patients. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      In the future, artificial intelligence may play a role in personalized medicine for individuals with clonal hematopoiesis. Hear more from Matteo Della Porta of @HumanitasMilano: 👉 https://t.co/ickxJ8VkdJ #MDSsm #HemOnc #AMLsm #IBC2025

  • Mashup Score: 3
    Assessing the risk of T-cell malignancy after CAR-T: findings from the DESCAR-T registry - 22 hour(s) ago

    Rémy Duléry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the risk of T-cell malignancy after CAR T-cell therapy, highlighting findings from the French DESCAR-T registry. Dr Duléry notes that, after analyzing data from over 3,000 patients receiving CAR-T, the registry found only one case of T-cell malignancy, translating to a risk of 0.03% of this complication. This reassuring data suggests that the benefits of CAR T-cell therapy outweigh the risks, particularly for patients with high-risk disease. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Is there cause for concern regarding the development of T-cell malignancy after #CARTCell therapy? Do the benefits of the treatment outweigh the risks? 💉🩸 Find out in our interview from #EBMT25 with @RemyDulery (@DanaFarber): 🎥 https://t.co/807vU4naXP #ImmunoOnc @TheEBMT

  • Mashup Score: 3
    Rescue strategies after failure of SCT in myelofibrosis - 1 day(s) ago

    In this interview, Francesco Passamonti, MD, University of Milan, Milan, Italy, outlines the rescue strategies available for patients with myelofibrosis (MF) who experience treatment failure after stem cell transplantation (SCT), highlighting the importance of monitoring mutations following SCT to detect molecular relapse early. Treatment options for this patient population include donor lymphocyte infusion (DLI), second transplantation, and agents such as hypomethylating agents (HMAs) and interferon. Prof. Passamonti notes that clinical trials are underway to explore mutant-specific therapies such as antibodies against mutant CALR. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      What are the rescue strategies available for patients with #myelofibrosis who experience treatment failure after transplantation? We caught up with Francesco Passamonti of @LaStatale at #EBMT25 to bring you valuable insight into this: 👉 https://t.co/k1FrSf0gvu #MPNsm #BMTsm

  • Mashup Score: 4
    The current approaches to prophylaxis in hemophilia and tailoring treatment to the individual - 2 day(s) ago

    Amy Shapiro, MD, Indiana University Hemophilia Center, Indianapolis, IN, outlines the current approaches to prophylaxis in hemophilia, highlighting the importance of individualized treatment plans based on the type of hemophilia, age, and patient preference. Dr Shapiro notes that prophylaxis is crucial for patients with severe hemophilia, but novel approaches are also appropriate for patients with moderate and mild disease who wish to receive prophylaxis for various personal reasons. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      #WHD2025 | What are the current approaches to prophylaxis in #hemophilia, and how should treatment be individualized?🩸 This World Hemophilia Day, check out our recent interview with Dr Amy Shapiro (@IUMedSchool) to find out: 🎥 https://t.co/HY1nZKoGfI #WeBleedToo #Hematology

  • Mashup Score: 5
    Hemophilia | VJHemOnc - 2 day(s) ago

    Explore the latest hemophilia updates, including expert interviews, features, podcasts and e-learning on The Hemophilia Channel from VJHemOnc.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Today is World Hemophilia Day!🌏🩸 This year's theme is “Access for all: Women & girls bleed too”.👩👧 Join the bleeding disorders community in raising awareness for people with #Hemophilia, and check out our hemophilia channel: 👉 https://t.co/zATIKH8B1n #WHD2025 #WeBleedToo https://t.co/ymiVxKLBJW

  • Mashup Score: 8
    Investigating patient outcomes by donor type if PTCy is used for GvHD prophylaxis: a CIBMTR analysis - 3 day(s) ago

    Steven Devine, MD, National Marrow Donor Program (NMDP), Minneapolis, MN, discusses the findings of a retrospective analysis of the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, which investigated whether the outcomes of patients undergoing transplantation differ by donor type when post-transplant cyclophosphamide (PTCy) is used for graft-versus-host disease (GvHD) prophylaxis. Dr Devine highlights that outcomes were comparable between donor types, meaning that donor availability should no longer be a barrier to access for patients in need of a bone marrow transplant. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      It was a pleasure to interview @DrStevenDevine of @nmdp_org recently to hear the findings of a @CIBMTR retrospective analysis investigating outcomes by donor type in patients undergoing transplantation with PTCy as GvHD prophylaxis: 👉 https://t.co/9z7jBF1G30 #EBMT25 #BMTsm

  • Mashup Score: 4
    Ongoing research and unmet needs in BPDCN - 3 day(s) ago

    Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses ongoing research and unmet needs in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Dr Papayannidis highlights the promising results of the approved drug tagraxofusp, and ongoing research investigating its combination. She emphasizes the importance of multidisciplinary teams and better diagnostic tools to address the significant challenges in managing this rare disease. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Don't forget to watch our recent interview with Cristina Papayannidis of @Unibo to hear about the ongoing research and unmet needs in #BPDCN. Click here: 👉 https://t.co/uUId5ifmFm 👈 #RareDisease #ISAL2025 #HemOnc

  • Mashup Score: 5
    Stratifying patients with MDS to optimize outcomes of alloSCT - 4 day(s) ago

    Valeria Santini, MD, University of Florence, Florence, Italy, discusses the importance of prognostically stratifying patients with myelodysplastic syndromes (MDS) to optimize outcomes of allogeneic stem cell transplantation (alloSCT). Prof. Santini highlights the value of the Molecular International Prognostic Scoring System (IPSS-M) in stratifying patients, particularly those with high-risk disease, and integrating clinical and molecular data to decide when and how to transplant patients for optimal outcomes. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      We were so happy that @Santin13Valeria of @UNI_FIRENZE stopped by to speak with us at the #EBMT25 meeting!😄 Watch the interview to hear Dr Santini discuss the importance of stratifying patients with MDS to optimize alloSCT outcomes: 🎥 https://t.co/BMlnfD1Nkg #MDSsm #BMTsm

Load More